JP5814488B2 - ジヒドロピリダジン−３，５−ジオン誘導体 - Google Patents
ジヒドロピリダジン−３，５−ジオン誘導体 Download PDFInfo
- Publication number
- JP5814488B2 JP5814488B2 JP2015505576A JP2015505576A JP5814488B2 JP 5814488 B2 JP5814488 B2 JP 5814488B2 JP 2015505576 A JP2015505576 A JP 2015505576A JP 2015505576 A JP2015505576 A JP 2015505576A JP 5814488 B2 JP5814488 B2 JP 5814488B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- trifluoromethyl
- phenyl
- hydroxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC(CCCC#N)(C(CC)C(C)C(C)CC1)C(C)=C(C(C2C(CCCCN)**2)=C)C1=C Chemical compound CCCC(CCCC#N)(C(CC)C(C)C(C)CC1)C(C)=C(C(C2C(CCCCN)**2)=C)C1=C 0.000 description 10
- VBRYHICLOXVNPA-UHFFFAOYSA-N CC(C)(C)OC(CCOCCOCCOCCO[O](c1ccc(C)cc1)([O-])=O)=O Chemical compound CC(C)(C)OC(CCOCCOCCOCCO[O](c1ccc(C)cc1)([O-])=O)=O VBRYHICLOXVNPA-UHFFFAOYSA-N 0.000 description 1
- PKCFPJQEQDLKSD-UHFFFAOYSA-N CC(C)(C)OC(CCOCCOCCOc(ccc(CN1N(C)C2(CCCC2)C(O)=C(C(Nc(ccc(C(F)(F)F)c2)c2-c2cc(C(F)(F)F)ncn2)=O)C1=O)c1F)c1F)=O Chemical compound CC(C)(C)OC(CCOCCOCCOc(ccc(CN1N(C)C2(CCCC2)C(O)=C(C(Nc(ccc(C(F)(F)F)c2)c2-c2cc(C(F)(F)F)ncn2)=O)C1=O)c1F)c1F)=O PKCFPJQEQDLKSD-UHFFFAOYSA-N 0.000 description 1
- DZPNUKRUYMUIMD-SNVBAGLBSA-N CC1(C)O[C@H](COCCCCCBr)CO1 Chemical compound CC1(C)O[C@H](COCCCCCBr)CO1 DZPNUKRUYMUIMD-SNVBAGLBSA-N 0.000 description 1
- PRJJXRMUMFKBRM-SECBINFHSA-N CC1(C)O[C@H](COCCC[Br]=C)CO1 Chemical compound CC1(C)O[C@H](COCCC[Br]=C)CO1 PRJJXRMUMFKBRM-SECBINFHSA-N 0.000 description 1
- VBRDIAXHJGPFQK-UHFFFAOYSA-N CCc(c(F)c(CN(C(CC(Nc(ccc(C(F)(F)F)c1)c1-c1ncnc(C(F)(F)F)c1)=O)=O)N(C)C1(CCC1)C(OC)=O)cc1)c1OCCN1CCOCC1 Chemical compound CCc(c(F)c(CN(C(CC(Nc(ccc(C(F)(F)F)c1)c1-c1ncnc(C(F)(F)F)c1)=O)=O)N(C)C1(CCC1)C(OC)=O)cc1)c1OCCN1CCOCC1 VBRDIAXHJGPFQK-UHFFFAOYSA-N 0.000 description 1
- CSIPMPYXUPIYEG-BUVRLJJBSA-N CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCCC1)C(OC)=O)c1F)c1F Chemical compound CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCCC1)C(OC)=O)c1F)c1F CSIPMPYXUPIYEG-BUVRLJJBSA-N 0.000 description 1
- CLLBVZMAXCBAFJ-UHFFFAOYSA-N CNC1(CCCC1)C(OC)=O Chemical compound CNC1(CCCC1)C(OC)=O CLLBVZMAXCBAFJ-UHFFFAOYSA-N 0.000 description 1
- XEMMEFHPILYXGE-AREMUKBSSA-N C[C@@](CCC1)(C(O)=C2C(Nc(ccc(C(F)(F)F)c3)c3-c3ncnc(C(F)(F)F)c3)=O)N1N(Cc(cccc1F)c1F)C2=O Chemical compound C[C@@](CCC1)(C(O)=C2C(Nc(ccc(C(F)(F)F)c3)c3-c3ncnc(C(F)(F)F)c3)=O)N1N(Cc(cccc1F)c1F)C2=O XEMMEFHPILYXGE-AREMUKBSSA-N 0.000 description 1
- DVKOGENZDLVFML-UHFFFAOYSA-N F[B](CN1CCOCC1)(F)[FH+] Chemical compound F[B](CN1CCOCC1)(F)[FH+] DVKOGENZDLVFML-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Luminescent Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015505576A JP5814488B2 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013051082 | 2013-03-13 | ||
| JP2013051082 | 2013-03-13 | ||
| JP2013132889 | 2013-06-25 | ||
| JP2013132889 | 2013-06-25 | ||
| JP2015505576A JP5814488B2 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン−３，５−ジオン誘導体 |
| PCT/JP2014/056778 WO2014142273A1 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン－３，５－ジオン誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015182722A Division JP6420738B2 (ja) | 2013-03-13 | 2015-09-16 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP5814488B2 true JP5814488B2 (ja) | 2015-11-17 |
| JPWO2014142273A1 JPWO2014142273A1 (ja) | 2017-02-16 |
Family
ID=51536921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505576A Active JP5814488B2 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン−３，５−ジオン誘導体 |
| JP2015182722A Active JP6420738B2 (ja) | 2013-03-13 | 2015-09-16 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015182722A Active JP6420738B2 (ja) | 2013-03-13 | 2015-09-16 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP3757093A1 (OSRAM) |
| JP (2) | JP5814488B2 (OSRAM) |
| KR (2) | KR101664460B1 (OSRAM) |
| CN (1) | CN105073715B (OSRAM) |
| AU (1) | AU2014230552B2 (OSRAM) |
| BR (1) | BR112015022092B1 (OSRAM) |
| CA (1) | CA2901868C (OSRAM) |
| CL (1) | CL2015002543A1 (OSRAM) |
| CR (1) | CR20150505A (OSRAM) |
| DK (1) | DK2975030T3 (OSRAM) |
| ES (1) | ES2811126T3 (OSRAM) |
| HR (1) | HRP20201211T1 (OSRAM) |
| HU (1) | HUE050577T2 (OSRAM) |
| IL (1) | IL240825B (OSRAM) |
| LT (1) | LT2975030T (OSRAM) |
| MX (1) | MX376532B (OSRAM) |
| MY (1) | MY174269A (OSRAM) |
| NZ (1) | NZ711182A (OSRAM) |
| PE (1) | PE20151535A1 (OSRAM) |
| PH (1) | PH12015501940A1 (OSRAM) |
| PL (1) | PL2975030T3 (OSRAM) |
| PT (1) | PT2975030T (OSRAM) |
| RS (1) | RS60911B1 (OSRAM) |
| RU (1) | RU2662832C2 (OSRAM) |
| SG (1) | SG11201507345RA (OSRAM) |
| SI (1) | SI2975030T1 (OSRAM) |
| TW (2) | TWI596095B (OSRAM) |
| UA (1) | UA118755C2 (OSRAM) |
| WO (1) | WO2014142273A1 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016040262A (ja) * | 2013-03-13 | 2016-03-24 | 中外製薬株式会社 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3928779B1 (en) * | 2014-09-12 | 2024-03-06 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification. |
| WO2018019721A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| WO2018019755A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| CN110885290A (zh) * | 2019-12-16 | 2020-03-17 | 阿里生物新材料（常州）有限公司 | 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法 |
| CN115734965B (zh) | 2020-06-26 | 2025-05-02 | 日本农药株式会社 | 芳基四氢哒嗪衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法 |
| WO2022221182A1 (en) * | 2021-04-12 | 2022-10-20 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc34a1 function |
| KR20240018523A (ko) | 2021-06-08 | 2024-02-13 | 추가이 세이야쿠 가부시키가이샤 | 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 |
| AR126060A1 (es) * | 2021-06-08 | 2023-09-06 | Chugai Pharmaceutical Co Ltd | Método para producir derivado de dihidropiridazin-3,5-diona |
| WO2023127805A1 (ja) | 2021-12-28 | 2023-07-06 | 日本農薬株式会社 | アリールテトラヒドロピリダジン誘導体又はその塩類及び該化合物を含有する殺虫剤並びにその使用方法 |
| WO2023219127A1 (ja) | 2022-05-11 | 2023-11-16 | 中外製薬株式会社 | 嚢胞性疾患を治療または予防するための医薬組成物 |
| CN116217862A (zh) * | 2023-03-21 | 2023-06-06 | 中国农业科学院农业环境与可持续发展研究所 | 一种可降解生物膜助剂的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003211381B9 (en) * | 2002-02-19 | 2009-07-30 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| CN1662529A (zh) * | 2002-06-19 | 2005-08-31 | 默克专利有限公司 | 作为磷酸二酯酶iv抑制剂的噻唑衍生物 |
| NZ563707A (en) * | 2005-05-18 | 2011-01-28 | Array Biopharma Inc | Heterocyclic inhibitors of MEK and methods of use thereof |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EA017900B1 (ru) * | 2006-11-03 | 2013-04-30 | Басф Се | Способ получения дифторметилпиразолилкарбоксилатов |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| WO2011048611A1 (en) * | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| US20130029973A1 (en) | 2010-04-28 | 2013-01-31 | Astellas Pharma Inc. | Tetrahydrobenzothiophene compound |
| WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590965B1 (en) * | 2010-07-07 | 2016-04-20 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| PL2772490T3 (pl) | 2011-10-27 | 2016-11-30 | Aminoalkilo-podstawiona pochodna n-tienylobenzamidu | |
| HRP20201211T1 (hr) * | 2013-03-13 | 2020-11-13 | Chugai Seiyaku Kabushiki Kaisha | Derivat dihidropiridazin-3,5-diona |
-
2014
- 2014-03-13 HR HRP20201211TT patent/HRP20201211T1/hr unknown
- 2014-03-13 JP JP2015505576A patent/JP5814488B2/ja active Active
- 2014-03-13 MY MYPI2015703054A patent/MY174269A/en unknown
- 2014-03-13 WO PCT/JP2014/056778 patent/WO2014142273A1/ja not_active Ceased
- 2014-03-13 BR BR112015022092-4A patent/BR112015022092B1/pt active IP Right Grant
- 2014-03-13 KR KR1020157029079A patent/KR101664460B1/ko active Active
- 2014-03-13 PE PE2015001917A patent/PE20151535A1/es unknown
- 2014-03-13 TW TW103109058A patent/TWI596095B/zh active
- 2014-03-13 PL PL14765619T patent/PL2975030T3/pl unknown
- 2014-03-13 NZ NZ711182A patent/NZ711182A/en unknown
- 2014-03-13 TW TW106123450A patent/TWI683811B/zh active
- 2014-03-13 AU AU2014230552A patent/AU2014230552B2/en active Active
- 2014-03-13 SG SG11201507345RA patent/SG11201507345RA/en unknown
- 2014-03-13 CN CN201480013485.6A patent/CN105073715B/zh active Active
- 2014-03-13 EP EP20185235.7A patent/EP3757093A1/en active Pending
- 2014-03-13 HU HUE14765619A patent/HUE050577T2/hu unknown
- 2014-03-13 ES ES14765619T patent/ES2811126T3/es active Active
- 2014-03-13 MX MX2015012537A patent/MX376532B/es active IP Right Grant
- 2014-03-13 EP EP14765619.3A patent/EP2975030B1/en active Active
- 2014-03-13 SI SI201431629T patent/SI2975030T1/sl unknown
- 2014-03-13 DK DK14765619.3T patent/DK2975030T3/da active
- 2014-03-13 LT LTEP14765619.3T patent/LT2975030T/lt unknown
- 2014-03-13 RU RU2015143507A patent/RU2662832C2/ru active
- 2014-03-13 PT PT147656193T patent/PT2975030T/pt unknown
- 2014-03-13 CA CA2901868A patent/CA2901868C/en active Active
- 2014-03-13 RS RS20201171A patent/RS60911B1/sr unknown
- 2014-03-13 KR KR1020167027514A patent/KR102072268B1/ko active Active
- 2014-03-13 UA UAA201509770A patent/UA118755C2/uk unknown
-
2015
- 2015-08-25 IL IL240825A patent/IL240825B/en active IP Right Grant
- 2015-09-03 PH PH12015501940A patent/PH12015501940A1/en unknown
- 2015-09-09 CL CL2015002543A patent/CL2015002543A1/es unknown
- 2015-09-16 JP JP2015182722A patent/JP6420738B2/ja active Active
- 2015-09-22 CR CR20150505A patent/CR20150505A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016040262A (ja) * | 2013-03-13 | 2016-03-24 | 中外製薬株式会社 | ジヒドロピリダジン−３，５−ジオン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5814488B2 (ja) | ジヒドロピリダジン−３，５−ジオン誘導体 | |
| JP5916975B1 (ja) | ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬 | |
| EP4577549A1 (en) | Compounds and methods for modulating her2 | |
| US9499553B2 (en) | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | |
| RU2811864C1 (ru) | Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата | |
| HK1212700B (en) | Dihydropyridazine-3,5-dione derivative | |
| HK1235279A1 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| HK1235279B (zh) | 含有钠依赖性磷酸转运蛋白抑制剂的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150428 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20150428 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20150604 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150713 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150901 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150917 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5814488 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |